A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.
Status:
Not yet recruiting
Trial end date:
2027-08-27
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to learn about the safety and effects of the study
medicine (called PF-07799933) administered as a single agent and in combination with other
study medicines (called binimetinib and cetuximab) in people with solid tumors.
This study is seeking participants who have an advanced solid tumor with a certain type of
abnormal gene called "BRAF" and available treatments are no longer effective in controlling
their cancer.
All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to
take by mouth, 1 or 2 times a day. Depending on the part of the study, participants may also
receive another study medicine:
- People with melanoma or other solid tumors may also receive binimetinib. Binimetinib
comes as a tablet to take by mouth, 2 times a day.
- People with colorectal cancer may also receive cetuximab. Cetuximab will be given weekly
(or every two weeks) in the clinic as a shot given in the vein or port (intravenous,
IV).
Participants may receive the study medicines for about 2 years. The study team will monitor
how each participant is doing with the study treatment during regular visits at the study
clinic.